Session V: Assessment of Response and Competing Risks

This session takes a closer look at NASH cirrhosis and the complications surrounding trials in this space. More specifically, competing risks of DILI, gallbladder disease and decompensation will be discussed. The utilization of NITs to monitor treatment response will be presented. 

SPEAKERS

Moderators:
Anna Mae Diehl, MD, FAASLD 
Stephen A. Harrison, MD, FAASLD

Presenters:
Manal F. Abdelmalek, MD, MPH, FAASLD - Emerging Therapies for NASH Cirrhosis
Vincent Wong, MD - Liver Histology, Functional and HVPG in NASH Cirrhosis
Rohit Loomba, MD - Non-invasive Biomarkers for Treatment Response
Naga P. Chalasani, MD, FAASLD - Competing Risks of DILI, Gall Bladder Disease, and Decompensation in Cirrhosis Trials and Their Impact on Trial Design